Dengvaxia Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Dengvaxia is a recombinant vaccine designed to protect against dengue fever, a viral illness transmitted by Aedes mosquitoes. It works by stimulating the immune system to generate a targeted response, helping prevent infection and severe complications, and supporting public health efforts in dengue-endemic regions.

The main types of dengvaxia include Dengvaxia itself and other related formulations. It is the first dengue vaccine approved for use, providing immunity against the virus that causes dengue and reducing the severity and frequency of infections. Dengvaxia is used in countries where dengue is prevalent to protect high-risk populations. It is distributed through hospitals, clinics, and public health programs, and applied in clinical settings for prevention in previously infected individuals, protection in high-risk areas, traveler immunization, and pediatric and adolescent use.

Tariffs have influenced the dengvaxia market by increasing costs related to imported vaccine raw materials, cold chain packaging, and specialized manufacturing inputs. These cost pressures have affected public health procurement programs, particularly in developing and dengue endemic regions. Asia pacific and latin america are most exposed due to high reliance on imported vaccines. At the same time, tariffs have encouraged regional vaccine manufacturing, strengthened local supply chains, and improved long term vaccine accessibility.

The dengvaxia market research report is one of a series of new reports from The Business Research Company that provides dengvaxia market statistics, including dengvaxia industry global market size, regional shares, competitors with a dengvaxia market share, detailed dengvaxia market segments, market trends and opportunities, and any further data you may need to thrive in the dengvaxia industry. This dengvaxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dengvaxia market size has grown rapidly in recent years. It will grow from $213.36 million in 2025 to $250.81 million in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to recurring dengue outbreaks, high disease burden in tropical regions, government led immunization initiatives, limited treatment options for dengue, rising public health awareness.

The dengvaxia market size is expected to see rapid growth in the next few years. It will grow to $473.95 million in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to expansion of vaccination coverage, increasing climate driven mosquito spread, growth in public health funding, improved vaccine delivery infrastructure, rising travel related immunization demand. Major trends in the forecast period include expansion of dengue vaccination programs, growing focus on endemic disease prevention, rising public health immunization campaigns, increased surveillance of mosquito-borne diseases, strengthening of pediatric and adolescent vaccination.

The high incidence of dengue is expected to drive the growth of the dengvaxia market in the coming years. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, severe pain, and in extreme cases, life-threatening complications such as dengue hemorrhagic fever or dengue shock syndrome. The rising prevalence of dengue is fueled by climate change, urbanization, increased travel, and the expansion of mosquito breeding grounds, leading to higher infection rates and greater demand for prevention and treatment. Dengvaxia helps prevent dengue by stimulating the immune system to produce a protective response against the virus, reducing the risk of infection and severe complications, and improving public health outcomes in endemic regions. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that the Americas recorded over 9.7 million dengue cases, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. Consequently, the high incidence of dengue is driving the growth of the dengvaxia market.

Rising healthcare expenditures are also expected to accelerate the growth of the dengvaxia market. Healthcare expenditure refers to the financial resources allocated by governments, private entities, or individuals for healthcare services, treatments, and related activities. Increases in healthcare spending are driven by growing demand for medical services, technological advancements, and the rising prevalence of chronic and infectious diseases, leading to greater investment in infrastructure and treatments. Expenditure on Dengvaxia emphasizes prevention, aiming to reduce the long-term costs of treating dengue and managing outbreaks. For instance, in May 2024, the Office for National Statistics reported that total healthcare expenditure in the UK increased by 5.6% in nominal terms from 2022 to 2023, a notable acceleration compared to the 0.9% growth observed in 2022. Therefore, growing healthcare spending is supporting the expansion of the dengvaxia market.

The rise in international travel is also expected to propel the growth of the dengvaxia market. International travel, including tourism, business, or educational trips, increases the risk of spreading infectious diseases such as dengue, which drives demand for preventive measures like vaccines. Dengvaxia is used to protect travelers from contracting dengue in endemic regions and to reduce the risk of cross-border disease transmission. For example, in May 2024, the Office for National Statistics reported that international visits to the UK increased from 31.2 million in 2022 to 38.0 million in 2023. Therefore, rising international travel is contributing to the growth of the dengvaxia market.

Major companies operating in the dengvaxia market are Sanofi Pasteur Inc.

Asia-Pacific was the largest region in the dengvaxia market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dengvaxia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The dengvaxia market consists of sales of dengvaxia (CYD-TDV), disposable syringes and needles, pre-filled syringes of dengvaxia, and unit-dose packaging. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dengvaxia Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses dengvaxia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dengvaxia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dengvaxia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Dengvaxia; Other Types
• 2) By Distribution Channel: Hospitals; Clinics; Public Health Programs
• 3) By Clinical Indication: Prevention In Previously Infected Individuals; Protection In High-Risk Regions; Traveler Immunization; Pediatric And Adolescent Use
• Companies Mentioned: Sanofi Pasteur Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.